{
  "url": "https://openlegislation.uk/eu-regulation-2016-1179/annex",
  "json_url": "https://openlegislation.uk/eu-regulation-2016-1179/annex.json",
  "legislation": "eur/2016/1179",
  "legislation_title": "Commission Regulation (EU) 2016/1179 of 19 July 2016 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance)",
  "legislation_url": "https://openlegislation.uk/eu-regulation-2016-1179",
  "path": "annex",
  "kind": "annex",
  "number": null,
  "heading": null,
  "text": "Table 3.1 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:\n(a) the entries corresponding to index numbers 607-331-00-5 and 609-066-00-0 are deleted;\n(b) the entries corresponding to index numbers, 006-035-00-8, 029-002-00-X, 602-020-00-0, 602-033-00-1, 603-055-00-4, 604-030-00-0, 604-092-00-9, 605-013-00-0, 605-022-00-X, 606-014-00-9, 606-021-00-7, 607-056-00-0, 607-059-00-7, 607-157-00-X, 607-172-00-1, 607-375-00-5, 607-623-00-2, 613-166-00-X, 613-121-00-4, 616-011-00-4, 616-037-00-6 and 616-207-00-X are replaced by the following entries respectively:\nIndex No\nInternational Chemical Identification\nEC No\nCAS No\nClassification\nLabelling\nSpecific Conc. Limits, M-factors\nNotes\nHazard Class and Category Code(s)\nHazard statement Code(s)\nPictogram, Signal Word Code(s)\nHazard statement Code(s)\nSuppl. Hazard statement Code(s)\n‘006-035-00-8\npirimicarb (ISO); 2-(dimethylamino)-5,6-dimethylpyrimidin-4-yl dimethylcarbamate\n245-430-1\n23103-98-2\nCarc. 2\nAcute Tox. 3\nAcute Tox. 3\nSkin Sens. 1\nAquatic Acute 1 Aquatic Chronic 1\nH351\nH331\nH301\nH317\nH400\nH410\nGHS08\nGHS06\nGHS09\nDgr\nH351\nH331\nH301\nH317\nH410\nM = 10\nM = 100’\n‘029-002-00-X\ndicopper oxide;\ncopper (I) oxide\n215-270-7\n1317-39-1\nAcute Tox. 4\nAcute Tox. 4\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH302\nH318\nH400\nH410\nGHS07\nGHS05\nGHS09\nDgr\nH332\nH302\nH318\nH410\nM = 100’\n‘602-020-00-0\n1,2-dichloropropane;\npropylene dichloride\n201-152-2\n78-87-5\nFlam. Liq. 2\nCarc. 1B\nAcute Tox. 4*\nAcute Tox. 4*\nH225\nH350\nH332\nH302\nGHS02\nGHS08\nGHS07\nDgr\nH225\nH350\nH332\nH302’\n‘602-033-00-1\nchlorobenzene\n203-628-5\n108-90-7\nFlam. Liq. 3\nAcute Tox. 4\nSkin Irrit. 2\nAquatic Chronic 2\nH226\nH332\nH315\nH411\nGHS02\nGHS07\nGHS09\nWng\nH226\nH332\nH315\nH411’\n‘603-055-00-4\npropylene oxide;\n1,2-epoxypropane; methyloxirane\n200-879-2\n75-56-9\nFlam. Liq. 1\nCarc. 1B\nMuta. 1B\nAcute Tox. 3\nAcute Tox. 3\nAcute Tox. 4\nSTOT SE 3\nEye Irrit. 2\nH224\nH350\nH340\nH331\nH311\nH302\nH335\nH319\nGHS02\nGHS08\nGHS06\nDgr\nH224\nH350\nH340\nH331\nH311\nH302\nH335\nH319’\n‘604-030-00-0\nbisphenol A;\n4,4′-isopropylidenediphenol\n201-245-8\n80-05-7\nRepr. 1B\nSTOT SE 3\nEye Dam. 1\nSkin Sens. 1\nH360F\nH335\nH318\nH317\nGHS08\nGHS05 GHS07\nDgr\nH360F\nH335\nH318\nH317’\n‘604-092-00-9\nphenol, dodecyl-, branched; [1]\nphenol, 2-dodecyl-, branched; [2]\nphenol, 3-dodecyl-, branched; [3]\nphenol, 4-dodecyl-, branched; [4]\nphenol, (tetrapropenyl) derivatives [5]\n310-154-3 [1]\n[2]\n[3]\n[4]\n[5]\n121158-58-5 [1]\n[2]\n[3]\n210555-94-5 [4]\n74499-35-7 [5]\nRepr. 1B\nSkin Corr. 1C\nEye Dam. 1\nAquatic Acute 1 Aquatic Chronic 1\nH360F\nH314\nH318\nH400\nH410\nGHS08\nGHS05\nGHS09\nDgr\nH360F\nH314\nH410\nM = 10\nM = 10’\n‘605-013-00-0\nchloralose (INN);\n(R)-1,2-O-(2,2,2-trichloroethylidene)-α-D-glucofuranose; glucochloralose; anhydroglucochloral\n240-016-7\n15879-93-3\nAcute Tox. 4*\nAcute Tox. 3\nSTOT SE 3\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH301\nH336\nH400\nH410\nGHS06\nGHS09\nDgr\nH332\nH301\nH336\nH410\nM = 10\nM = 10\nC’\n‘605-022-00-X\nglutaral; glutaraldehyde;\n1,5-pentanedial\n203-856-5\n111-30-8\nAcute Tox. 2\nAcute Tox. 3\nSTOT SE 3\nSkin Corr. 1B\nResp. Sens. 1\nSkin Sens. 1A\nAquatic Acute 1\nAquatic Chronic 2\nH330\nH301\nH335\nH314\nH334\nH317\nH400\nH411\nGHS06\nGHS05\nGHS08\nGHS09\nDgr\nH330\nH301\nH335\nH314\nH334\nH317\nH410\nEUH071\nSTOT SE 3; H335: 0,5 % ≤ C < 5 %\nM = 1’\n‘606-014-00-9\nchlorophacinone (ISO);\n2-[(4-chlorophenyl)(phenyl)acetyl]-1H-indene-1,3(2H)-dione\n223-003-0\n3691-35-8\nRepr. 1B\nAcute Tox. 1\nAcute Tox. 1\nAcute Tox. 1\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH360D\nH330\nH310\nH300\nH372 (blood)\nH400\nH410\nGHS08\nGHS06\nGHS09\nDgr\nH360D\nH330\nH310\nH300\nH372 (blood)\nH410\nRepr. 1B; H360D:\nC ≥ 0,003 %\nSTOT RE 1; H372 (blood): C ≥ 0,1 %\nSTOT RE 2; H373 (blood):\n0,01 % ≤ C < 0,1 %\nM = 1\nM = 1’\n‘606-021-00-7\nN-methyl-2-pyrrolidone; 1-methyl-2-pyrrolidone\n212-828-1\n872-50-4\nRepr. 1B\nSTOT SE 3\nSkin Irrit. 2\nEye Irrit. 2\nH360D***\nH335\nH315\nH319\nGHS08\nGHS07\nDgr\nH360D***\nH335\nH315\nH319\nSTOT SE 3; H335: C ≥ 10 %’\n‘607-056-00-0\nwarfarin (ISO);\n4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one; [1]\n(S)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone; [2]\n(R)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone [3]\n201-377-6\n[1]\n226-907-3\n[2]\n226-908-9\n[3]\n81-81-2 [1]\n5543-57-7\n[2]\n5543-58-8\n[3]\nRepr. 1A\nAcute Tox. 1\nAcute Tox. 1\nAcute Tox. 2\nSTOT RE 1\nAquatic Chronic 2\nH360D\nH330\nH310\nH300\nH372 (blood)\nH411\nGHS08\nGHS06\nGHS09\nDgr\nH360D\nH330\nH310\nH300\nH372 (blood)\nH411\nRepr. 1A; H360D:\nC ≥ 0,003 %\nSTOT RE 1; H372 (blood): C ≥ 0,5 %\nSTOT RE 2; H373 (blood): 0,05 % ≤ C < 0,5 %’\n‘607-059-00-7\ncoumatetralyl (ISO); 4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthyl)coumarin\n227-424-0\n5836-29-3\nRepr. 1B\nAcute Tox. 2\nAcute Tox. 3\nAcute Tox. 2\nSTOT RE 1\nAquatic Chronic 1\nH360D\nH330\nH311\nH300\nH372 (blood)\nH410\nGHS08\nGHS06\nGHS09\nDgr\nH360D\nH330\nH311\nH300\nH372 (blood)\nH410\nRepr. 1B; H360D: C ≥ 0,003 %\nSTOT RE 1; H372 (blood): C ≥ 1,0 %\nSTOT RE 2; H373 (blood) 0,1 % ≤ C < 1,0 %\nM = 10’\n‘607-157-00-X\ndifenacoum (ISO); 3-(3-biphenyl-4-yl-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarin\n259-978-4\n56073-07-5\nRepr. 1B\nAcute Tox. 1\nAcute Tox. 1\nAcute Tox. 1\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH360D\nH330\nH310\nH300\nH372 (blood)\nH400\nH410\nGHS08\nGHS06\nGHS09\nDgr\nH360D\nH330\nH310\nH300\nH372 (blood)\nH410\nRepr. 1B; H360D:\nC ≥ 0,003 %\nSTOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):\n0,002 % ≤ C < 0,02 %\nM = 10\nM = 10’\n‘607-172-00-1\nbrodifacoum (ISO);\n4-hydroxy-3-(3-(4′-bromo-4-biphenylyl)-1,2,3,4-tetrahydro-1-naphthyl)coumarin\n259-980-5\n56073-10-0\nRepr. 1A\nAcute Tox. 1\nAcute Tox. 1\nAcute Tox. 1\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH360D\nH330\nH310\nH300\nH372 (blood)\nH400\nH410\nGHS08\nGHS06\nGHS09\nDgr\nH360D\nH330\nH310\nH300\nH372 (blood)\nH410\nRepr. 1A; H360D:\nC ≥ 0,003 %\nSTOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):\n0,002 % ≤ C < 0,02 %\nM = 10\nM = 10’\n‘607-375-00-5\nflocoumafen (ISO); reaction mass of: cis-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin and trans-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin\n421-960-0\n90035-08-8\nRepr. 1B\nAcute Tox. 1\nAcute Tox. 1\nAcute Tox. 1\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH360D\nH330\nH310\nH300\nH372 (blood)\nH400\nH410\nGHS08\nGHS06\nGHS09\nDgr\nH360D\nH330\nH310\nH300\nH372 (blood)\nH410\nRepr. 1B; H360D:\nC ≥ 0,003 %\nSTOT RE 1; H372 (blood): C ≥ 0,05 %\nSTOT RE 2; H373 (blood):\n0,005 % ≤ C < 0,05 %\nM = 10\nM = 10’\n‘607-623-00-2\ndiisobutyl phthalate\n201-553-2\n84-69-5\nRepr. 1B\nH360Df\nGHS08\nDgr\nH360Df’\n‘613-166-00-X\nflumioxazin (ISO);\n2-[7-fluoro-3-oxo-4-(prop-2-yn-1-yl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione\n—\n103361-09-7\nRepr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH360D\nH400\nH410\nGHS08\nGHS09\nDgr\nH360D\nH410\nM = 1 000\nM = 1 000’\n‘613-121-00-4\nchlorsulfuron (ISO); 2-chloro-N-[[(4-methoxy-6-methyl-1,3,5-triazin-2- yl)amino]carbonyl]benzenesulphonamide\n265-268-5\n64902-72-3\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM = 1 000\nM = 100’\n‘616-011-00-4\nN,N-dimethylacetamide\n204-826-4\n127-19-5\nRepr. 1B\nAcute Tox. 4*\nAcute Tox. 4*\nH360D***\nH332\nH312\nGHS08\nGHS07\nDgr\nH360D***\nH332\nH312’\n‘616-037-00-6\nacetochlor (ISO); 2-chloro-N-(ethoxymethyl)-N-(2-ethyl-6-methylphenyl)acetamide\n251-899-3\n34256-82-1\nCarc. 2\nRepr. 2\nAcute Tox. 4\nSTOT SE 3\nSTOT RE 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH361f\nH332\nH335\nH373 (kidney)\nH315\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH361f\nH332\nH335\nH373 (kidney)\nH315\nH317\nH410\nM = 1 000\nM = 100’\n‘616-207-00-X\npolyhexamethylene biguanide hydrochloride;\nPHMB\n—\n32289-58-0\n27083-27-8\nCarc. 2\nAcute Tox. 2\nAcute Tox. 4\nSTOT RE 1\nEye Dam. 1\nSkin Sens. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH330\nH302\nH372 (respiratory tract) (inhalation)\nH318\nH317\nH400\nH410\nGHS08\nGHS06\nGHS05\nGHS09\nDgr\nH351\nH330\nH302\nH372 (respiratory tract) (inhalation)\nH318\nH317\nH410\nM = 10\nM = 10’\n(c) the following entries are inserted in accordance with the order of the index numbers:\nIndex No\nInternational Chemical Identification\nEC No\nCAS No\nClassification\nLabelling\nSpecific Conc. Limits, M-factors\nNotes\nHazard Class and Category Code(s)\nHazard statement Code(s)\nPictogram, Signal Word Code(s)\nHazard statement Code(s)\nSuppl. Hazard statement Code(s)\n‘005-020-00-3\ndisodium octaborate anhydrous; [1]\ndisodium octaborate tetrahydrate [2]\n234-541-0 [1]\n234-541-0 [2]\n12008-41-2 [1]\n12280-03-4 [2]\nRepr. 1B\nH360FD\nGHS08\nDgr\nH360FD’\n‘014-046-00-4\ne-glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following representative composition (% given by weight): SiO2 50,0-56,0 %, Al2O3 13,0-16,0 %, B2O3 5,8-10,0 %, Na2O < 0,6 %, K2O < 0,4 %, CaO 15,0-24,0 %, MgO < 5,5 %, Fe2O3 < 0,5 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).]\n—\n—\nCarc. 1B\nH350i\nGHS08\nDgr\nH350i\nA’\n‘014-047-00-X\nglass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following composition (% given by weight): SiO2 55,0-60,0 %, Al2O3 4,0-7,0 %, B2O3 8,0-11,0 %, ZrO2 0,0-4,0 %, Na2O 9,5-13,5 %, K2O 0,0-4,0 %, CaO 1,0-5,0 %, MgO 0,0-2,0 %, Fe2O3 < 0,2 %, ZnO 2,0-5,0 %, BaO 3,0-6,0 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).]\n—\n—\nCarc. 2\nH351 (inhalation)\nGHS08\nWng\nH351 (inhalation)\nA’\n‘029-015-00-0\ncopper thiocyanate\n214-183-1\n1111-67-7\nAquatic Acute 1 Aquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nEUH032\nM = 10’\n‘029-016-00-6\ncopper(II) oxide\n215-269-1\n1317-38-0\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM = 100’\n‘029-017-00-1\ndicopper chloride trihydroxide\n215-572-9\n1332-65-6\nAcute Tox. 4\nAcute Tox. 3\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH332\nH301\nH410\nM = 10’\n‘029-018-00-7\ntetracopper hexahydroxide sulphate; [1]\ntetracopper hexahydroxide sulphate hydrate [2]\n215-582-3 [1]\n215-582-3 [2]\n1333-22-8 [1]\n12527-76-3 [2]\nAcute Tox. 4\nAquatic Acute 1 Aquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\nM = 10’\n‘029-019-01-X\ncopper flakes (coated with aliphatic acid)\n—\n—\nAcute Tox. 3\nAcute Tox. 4\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH302\nH319\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH302\nH319\nH410\nM = 10’\n‘029-020-00-8\ncopper(II) carbonate--copper(II) hydroxide (1:1)\n235-113-6\n12069-69-1\nAcute Tox. 4\nAcute Tox. 4\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH302\nH319\nH400\nH410\nGHS07\nGHS09\nWng\nH332\nH302\nH319\nH410\nM = 10’\n‘029-021-00-3\ncopper dihydroxide;\ncopper(II) hydroxide\n243-815-9\n20427-59-2\nAcute Tox. 2\nAcute Tox. 4\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH302\nH318\nH400\nH410\nGHS06\nGHS05\nGHS09\nDgr\nH330\nH302\nH318\nH410\nM = 10’\n‘029-022-00-9\nbordeaux mixture;\nreaction products of copper sulphate with calcium dihydroxide\n—\n8011-63-0\nAcute Tox. 4\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH318\nH400\nH410\nGHS07\nGHS05\nGHS09\nDgr\nH332\nH318\nH410\nM = 10’\n‘029-023-00-4\ncopper sulphate pentahydrate\n231-847-6\n7758-99-8\nAcute Tox. 4\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH318\nH400\nH410\nGHS07\nGHS05\nGHS09\nDgr\nH302\nH318\nH410\nM = 10’\n‘082-013-00-1\nlead powder;\n[particle diameter < 1 mm]\n231-100-4\n7439-92-1\nRepr. 1A\nLact.\nH360FD\nH362\nGHS08\nDgr\nH360FD\nH362\nRepr. 1A; H360D: C ≥ 0,03 %’\n‘082-014-00-7\nlead massive:\n[particle diameter ≥ 1 mm]\n231-100-4\n7439-92-1\nRepr. 1A\nLact.\nH360FD\nH362\nGHS08\nDgr\nH360FD\nH362’\n‘605-040-00-8\nhydroxyisohexyl 3-cyclohexene carboxaldehyde (INCI); reaction mass of 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde and 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [1]\n4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [2]\n3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde [3]\n- [1]\n250-863-4 [2]\n257-187-9 [3]\n130066-44-3 [1]\n31906-04-4 [2]\n51414-25-6 [3]\nSkin Sens. 1A\nH317\nGHS07\nWng\nH317’\n‘607-716-00-8\nbromadiolone (ISO); 3-[3-(4′-bromobiphenyl-4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxy-2H-chromen-2-one\n249-205-9\n28772-56-7\nRepr. 1B\nAcute Tox. 1\nAcute Tox. 1\nAcute Tox. 1\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH360D\nH330\nH310\nH300\nH372 (blood)\nH400\nH410\nGHS08\nGHS06\nGHS09\nDgr\nH360D\nH330\nH310\nH300\nH372 (blood)\nH410\nRepr. 1B; H360D:\nC ≥ 0,003 %\nSTOT RE 1; H372 (blood): C ≥ 0,005 % STOT RE 2; H373 (blood):\n0,0005 % ≤ C < 0,005 %\nM = 1\nM = 1’\n‘607-717-00-3\ndifethialone (ISO);\n3-[3-(4′-bromobiphenyl-4-yl)-1,2,3,4-tetrahydronaphthalen-1-yl]-4-hydroxy-2H-1-benzothiopyran-2-one\n—\n104653-34-1\nRepr. 1B\nAcute Tox. 1\nAcute Tox. 1\nAcute Tox. 1\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH360D\nH330\nH310\nH300\nH372 (blood)\nH400\nH410\nGHS08\nGHS06\nGHS09\nDgr\nH360D\nH330\nH310\nH300\nH372 (blood)\nH410\nEUH070\nRepr. 1B; H360D:\nC ≥ 0,003 %\nSTOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):\n0,002 % ≤ C < 0,02 %\nM = 100\nM = 100’\n‘607-718-00-9\nperfluorononan-1-oic acid [1] and its sodium [2] and ammonium [3] salts\n206-801-3 [1]\n[2]\n[3]\n375-95-1 [1]\n21049-39-8 [2]\n4149-60-4 [3]\nCarc. 2\nRepr. 1B\nLact.\nAcute Tox. 4\nAcute Tox. 4\nSTOT RE 1\nEye Dam. 1\nH351\nH360Df\nH362\nH332\nH302\nH372 (liver, thymus, spleen)\nH318\nGSH08\nGSH07\nGHS05\nDgr\nH351\nH360Df\nH362\nH332\nH302\nH372 (liver, thymus, spleen)\nH318’\n‘607-719-00-4\ndicyclohexyl phthalate\n201-545-9\n84-61-7\nRepr. 1B\nSkin Sens. 1\nH360D\nH317\nGHS08\nGHS07\nDgr\nH360D\nH317’\n‘608-067-00-3\n3,7-dimethylocta-2,6-dienenitrile\n225-918-0\n5146-66-7\nMuta. 1B\nH340\nGHS08\nDgr\nH340’\n‘612-288-00-0\nbupirimate (ISO);\n5-butyl-2-ethylamino-6-methylpyrimidin-4-yl dimethylsulphamate\n255-391-2\n41483-43-6\nCarc. 2\nSkin Sens. 1B\nAquatic Chronic 1\nH351\nH317\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH317\nH410\nM = 1’\n‘612-289-00-6\ntriflumizole (ISO);\n(1E)-N-[4-chloro-2-(trifluoromethyl)phenyl]-1-(1H-imidazol-1-yl)-2-propoxyethanimine\n—\n68694-11-1\nRepr. 1B\nAcute Tox. 4\nSTOT RE 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH360D\nH302\nH373 (liver)\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH360D\nH302\nH373 (liver)\nH317\nH410\nM = 1\nM = 1’\n‘616-218-00-X\nbenzovindiflupyr (ISO); N-[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide\n—\n1072957-71-1\nAcute Tox. 3\nAcute Tox. 3\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH301\nH410\nM = 100\nM = 100’\n‘616-219-00-5\nfluopyram (ISO); N-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2-(trifluoromethyl)benzamide\n—\n658066-35-4\nAquatic Chronic 2\nH411\nGHS09\nH411’\n‘616-220-00-0\npencycuron (ISO); 1-[(4-chlorophenyl)methyl]-1-cyclopentyl-3-phenylurea\n266-096-3\n66063-05-6\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM = 1\nM = 1’\n‘617-023-00-2\ntert-butyl hydroperoxide\n200-915-7\n75-91-2\nMuta. 2\nH341\nGHS08\nWng\nH341’",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eur/2016/1179/annex",
    "retrieved_at": "2026-11-01T14:45:40.846745+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}